Three monoclonal antibody therapies (benralizumab, mepolizumab and omalizumab) are available in Australia for the treatment of patients with severe asthma whose asthma is uncontrolled despite optimised standard treatment including high-dose inhaled corticosteroids and long-acting beta2 agonists (Table 1).
This information paper for health professionals provides a summary of the latest evidence on the prevalence and impact of poor technique, alongside checklists for correct use of the main inhalers available in Australia. It is not intended as a patient hand-out.
We have limited stock of our print resources so please only order the quantities that you need.
If you are ordering for a clinic and require large quantities of this resource, please contact us via email with your request.